Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Chinook Therapeutics, Inc. (ADRO) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Chinook Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1435049.
Total stock buying since 2015: $32,811,843.
Total stock sales since 2015: $104,973,572.
Total stock option exercises since 2015: $2,200,602.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 797,490 | $17,679,744 | 170,619 | $24,500 |
| 2022 | 5,000 | $65,150 | 2,040,436 | $32,669,312 | 120,782 | $6,125 |
| 2021 | 1,436,500 | $19,664,436 | 1,765,000 | $24,713,032 | 177,207 | $40,898 |
| 2020 | 10,500 | $141,993 | 146,820 | $273,707 | 61,453 | $25,653 |
| 2019 | 0 | $0 | 126,952 | $309,850 | 92,742 | $72,430 |
| 2018 | 0 | $0 | 386,022 | $2,970,146 | 342,572 | $283,988 |
| 2017 | 0 | $0 | 1,121,311 | $11,782,030 | 1,164,200 | $873,654 |
| 2016 | 0 | $0 | 530,680 | $7,948,745 | 554,972 | $539,346 |
| 2015 | 761,192 | $12,940,264 | 229,364 | $6,627,006 | 261,684 | $334,008 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-08 | 0 | $0 | 1,168 | $45,585 | 0 | $0 |
| 2023-07 | 0 | $0 | 0 | $0 | 3,333 | $0 |
| 2023-05 | 0 | $0 | 1,155 | $26,911 | 19,800 | $0 |
| 2023-04 | 0 | $0 | 326,732 | $6,824,242 | 29,699 | $11,375 |
| 2023-03 | 0 | $0 | 400,000 | $9,100,000 | 0 | $0 |
| 2023-02 | 0 | $0 | 15,046 | $357,325 | 36,289 | $0 |
| 2023-01 | 0 | $0 | 53,389 | $1,325,681 | 81,498 | $13,125 |
| 2022-10 | 0 | $0 | 10,917 | $214,977 | 54,530 | $0 |
| 2022-08 | 0 | $0 | 5,000 | $100,000 | 5,000 | $1,750 |
| 2022-07 | 0 | $0 | 5,000 | $90,470 | 5,000 | $1,750 |
| 2022-05 | 5,000 | $65,150 | 0 | $0 | 0 | $0 |
| 2022-04 | 0 | $0 | 5,000 | $76,810 | 5,000 | $1,750 |
| 2022-02 | 0 | $0 | 14,519 | $187,055 | 51,252 | $875 |
| 2022-01 | 0 | $0 | 2,000,000 | $32,000,000 | 0 | $0 |
| 2021-12 | 0 | $0 | 0 | $0 | 56,414 | $14,000 |
| 2021-11 | 1,215,000 | $17,010,000 | 45,000 | $653,032 | 17,500 | $7,175 |
| 2021-10 | 0 | $0 | 0 | $0 | 63,293 | $4,323 |
| 2021-09 | 2,000 | $24,000 | 20,000 | $260,000 | 20,000 | $8,400 |
| 2021-08 | 218,500 | $2,615,996 | 1,700,000 | $23,800,000 | 0 | $0 |
| 2021-06 | 0 | $0 | 0 | $0 | 20,000 | $7,000 |
| 2021-05 | 1,000 | $14,440 | 0 | $0 | 0 | $0 |
| 2020-12 | 4,000 | $52,634 | 0 | $0 | 20,000 | $7,000 |
| 2020-11 | 6,500 | $89,359 | 0 | $0 | 0 | $0 |
| 2020-09 | 0 | $0 | 47,246 | $113,011 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-08-01 | King Andrew James (Chief Scientific Officer) | Sale | 1,168 | 39.03 | 45,585 |
| 2023-07-29 | King Andrew James (Chief Scientific Officer) | Option Ex | 3,333 | .00 | 0 |
| 2023-05-30 | Greenman William Mariner (Director) | Sale | 1,155 | 23.30 | 26,911 |
| 2023-05-26 | Thomas Dolca (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-05-26 | Jerel Davis (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-05-26 | Haghighat Ross (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-05-26 | Greenman William Mariner (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-05-26 | Akkaraju Srinivas (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-05-26 | Griffin Michelle Renee (Director) | Option Ex | 3,300 | .00 | 0 |
| 2023-04-24 | Dobmeier Eric (President, CEO) | Sale | 25,000 | 21.92 | 547,950 |
| 2023-04-24 | Dobmeier Eric (President, CEO) | Option Ex | 25,000 | .42 | 10,500 |
| 2023-04-17 | Jerel Davis (Director) | Sale | 295,808 | 20.75 | 6,138,311 |
| 2023-04-04 | Krishnan Mahesh (Director) | Sale | 924 | 23.01 | 21,261 |
| 2023-04-03 | King Andrew James (Chief Scientific Officer) | Sale | 5,000 | 23.34 | 116,720 |
| 2023-04-03 | King Andrew James (Chief Scientific Officer) | Option Ex | 2,500 | .35 | 875 |
| 2023-04-01 | Krishnan Mahesh (Director) | Option Ex | 2,199 | .00 | 0 |
| 2023-03-01 | Jerel Davis (Director) | Sale | 400,000 | 22.75 | 9,100,000 |
| 2023-02-10 | Frohlich Tom (Chief Operating Officer) | Sale | 3,700 | 23.75 | 87,871 |
| 2023-02-10 | Frohlich Tom (Chief Operating Officer) | Option Ex | 6,803 | .00 | 0 |
| 2023-02-10 | King Andrew James (Chief Scientific Officer) | Sale | 2,392 | 23.75 | 56,807 |
| 2023-02-10 | King Andrew James (Chief Scientific Officer) | Option Ex | 6,803 | .00 | 0 |
| 2023-02-10 | Dobmeier Eric (President, CEO) | Sale | 8,097 | 23.75 | 192,295 |
| 2023-02-10 | Dobmeier Eric (President, CEO) | Option Ex | 20,248 | .00 | 0 |
| 2023-02-10 | Bjerkholt Eric (Chief Financial Officer) | Sale | 857 | 23.75 | 20,352 |
| 2023-02-10 | Bjerkholt Eric (Chief Financial Officer) | Option Ex | 2,435 | .00 | 0 |
| 2023-01-31 | Frohlich Tom (Chief Operating Officer) | Sale | 4,566 | 24.68 | 112,698 |
| 2023-01-31 | Frohlich Tom (Chief Operating Officer) | Option Ex | 8,333 | .00 | 0 |
| 2023-01-31 | King Andrew James (Chief Scientific Officer) | Sale | 3,244 | 24.68 | 80,068 |
| 2023-01-31 | King Andrew James (Chief Scientific Officer) | Option Ex | 8,333 | .00 | 0 |
| 2023-01-31 | Dobmeier Eric (President, CEO) | Sale | 7,688 | 24.68 | 189,755 |
| 2023-01-31 | Dobmeier Eric (President, CEO) | Option Ex | 24,999 | .00 | 0 |
| 2023-01-31 | Bjerkholt Eric (Chief Financial Officer) | Sale | 2,891 | 24.68 | 71,355 |
| 2023-01-31 | Bjerkholt Eric (Chief Financial Officer) | Option Ex | 7,333 | .00 | 0 |
| 2023-01-30 | Dobmeier Eric (President, CEO) | Sale | 25,000 | 24.55 | 613,625 |
| 2023-01-30 | Dobmeier Eric (President, CEO) | Option Ex | 25,000 | .42 | 10,500 |
| 2023-01-03 | King Andrew James (Chief Scientific Officer) | Sale | 10,000 | 25.82 | 258,180 |
| 2023-01-03 | King Andrew James (Chief Scientific Officer) | Option Ex | 7,500 | .35 | 2,625 |
| 2022-10-06 | Frohlich Tom (Chief Operating Officer) | Sale | 7,360 | 19.69 | 144,933 |
| 2022-10-06 | Frohlich Tom (Chief Operating Officer) | Option Ex | 13,582 | .00 | 0 |
| 2022-10-06 | King Andrew James (Chief Scientific Officer) | Sale | 3,557 | 19.69 | 70,044 |
| 2022-10-06 | King Andrew James (Chief Scientific Officer) | Option Ex | 10,152 | .00 | 0 |
| 2022-10-06 | Dobmeier Eric (President, CEO) | Option Ex | 30,796 | .00 | 0 |
| 2022-08-04 | King Andrew James (Chief Scientific Officer) | Sale | 5,000 | 20.00 | 100,000 |
| 2022-08-04 | King Andrew James (Chief Scientific Officer) | Option Ex | 5,000 | .35 | 1,750 |
| 2022-07-11 | King Andrew James (Chief Scientific Officer) | Sale | 5,000 | 18.09 | 90,470 |
| 2022-07-11 | King Andrew James (Chief Scientific Officer) | Option Ex | 5,000 | .35 | 1,750 |
| 2022-05-25 | Dobmeier Eric (President, CEO) | Buy | 5,000 | 13.03 | 65,150 |
| 2022-04-11 | King Andrew James (Chief Scientific Officer) | Sale | 5,000 | 15.36 | 76,810 |
| 2022-04-11 | King Andrew James (Chief Scientific Officer) | Option Ex | 5,000 | .35 | 1,750 |
| 2022-02-18 | King Andrew James (Chief Scientific Officer) | Sale | 2,500 | 13.00 | 32,500 |
| 2022-02-11 | Frohlich Tom (Chief Operating Officer) | Sale | 3,735 | 12.74 | 47,587 |
| 2022-02-11 | Glicklich Alan (Chief Medical Officer) | Sale | 2,391 | 12.74 | 30,463 |
| 2022-02-11 | King Andrew James (Chief Scientific Officer) | Sale | 2,498 | 12.74 | 31,827 |
| 2022-02-11 | Bjerkholt Eric (Chief Financial Officer) | Sale | 895 | 12.74 | 11,403 |
| 2022-02-10 | Frohlich Tom (Chief Operating Officer) | Option Ex | 6,801 | .00 | 0 |
| 2022-02-10 | Glicklich Alan (Chief Medical Officer) | Option Ex | 5,668 | .00 | 0 |
| 2022-02-10 | King Andrew James (Chief Scientific Officer) | Sale | 2,500 | 13.31 | 33,275 |
| 2022-02-10 | King Andrew James (Chief Scientific Officer) | Option Ex | 9,301 | .17 | 875 |
| 2022-02-10 | Dobmeier Eric (President, CEO) | Option Ex | 20,247 | .00 | 0 |
| 2022-02-10 | Bjerkholt Eric (Chief Financial Officer) | Option Ex | 2,434 | .00 | 0 |
| 2022-01-03 | Versant Voyageurs I Parallel, L.p. (10% Owner) | Sale | 1,000,000 | 16.00 | 16,000,000 |
| 2022-01-03 | Jerel Davis (Director) | Sale | 1,000,000 | 16.00 | 16,000,000 |
| 2021-12-23 | Dobmeier Eric (President, CEO) | Option Ex | 40,000 | .35 | 14,000 |
| 2021-12-01 | Bjerkholt Eric (Chief Financial Officer) | Option Ex | 16,414 | .00 | 0 |
| 2021-11-15 | Akkaraju Srinivas (Director) | Buy | 1,215,000 | 14.00 | 17,010,000 |
| 2021-11-10 | Frohlich Tom (Chief Operating Officer) | Sale | 6,230 | 15.48 | 96,440 |
| 2021-11-09 | King Andrew James (Chief Scientific Officer) | Sale | 5,000 | 13.53 | 67,660 |
| 2021-11-09 | King Andrew James (Chief Scientific Officer) | Option Ex | 2,500 | .35 | 875 |
| 2021-11-08 | Frohlich Tom (Chief Operating Officer) | Sale | 13,770 | 15.17 | 208,932 |
| 2021-11-05 | Frohlich Tom (Chief Operating Officer) | Sale | 20,000 | 14.00 | 280,000 |
| 2021-11-05 | Frohlich Tom (Chief Operating Officer) | Option Ex | 15,000 | .42 | 6,300 |
| 2021-10-21 | Greenman William Mariner (Director) | Option Ex | 1,663 | 2.60 | 4,323 |
| 2021-10-06 | Frohlich Tom (Chief Operating Officer) | Option Ex | 13,580 | .00 | 0 |
| 2021-10-06 | Glicklich Alan (Chief Medical Officer) | Option Ex | 7,103 | .00 | 0 |
| 2021-10-06 | King Andrew James (Chief Scientific Officer) | Option Ex | 10,151 | .00 | 0 |
| 2021-10-06 | Dobmeier Eric (President, CEO) | Option Ex | 30,796 | .00 | 0 |
| 2021-09-24 | Frohlich Tom (Chief Operating Officer) | Sale | 20,000 | 13.00 | 260,000 |
| 2021-09-24 | Frohlich Tom (Chief Operating Officer) | Option Ex | 20,000 | .42 | 8,400 |
| 2021-09-20 | Dobmeier Eric (President, CEO) | Buy | 2,000 | 12.00 | 24,000 |
| 2021-08-27 | Versant Voyageurs I Parallel, L.p. (10% Owner) | Sale | 850,000 | 14.00 | 11,900,000 |
| 2021-08-27 | Jerel Davis (Director) | Sale | 850,000 | 14.00 | 11,900,000 |
| 2021-08-19 | Dobmeier Eric (President, CEO) | Buy | 3,000 | 12.00 | 36,000 |
| 2021-08-18 | Akkaraju Srinivas (Director) | Buy | 208,500 | 11.98 | 2,497,830 |
| 2021-08-18 | Dobmeier Eric (President, CEO) | Buy | 7,000 | 11.74 | 82,166 |
| 2021-06-14 | Dobmeier Eric (President, CEO) | Option Ex | 20,000 | .35 | 7,000 |
| 2021-05-14 | Dobmeier Eric (President, CEO) | Buy | 1,000 | 14.44 | 14,440 |
| 2020-12-21 | Dobmeier Eric (President, CEO) | Option Ex | 20,000 | .35 | 7,000 |
| 2020-12-09 | Dobmeier Eric (President, CEO) | Buy | 2,000 | 13.07 | 26,150 |
| 2020-12-08 | Dobmeier Eric (President, CEO) | Buy | 2,000 | 13.24 | 26,484 |
| 2020-11-23 | Dobmeier Eric (President, CEO) | Buy | 929 | 13.67 | 12,698 |
| 2020-11-20 | Dobmeier Eric (President, CEO) | Buy | 571 | 13.69 | 7,816 |
| 2020-11-19 | Dobmeier Eric (President, CEO) | Buy | 500 | 13.50 | 6,750 |
| 2020-11-11 | Dobmeier Eric (President, CEO) | Buy | 2,500 | 13.75 | 34,375 |
| 2020-11-10 | Dobmeier Eric (President, CEO) | Buy | 2,000 | 13.86 | 27,720 |
| 2020-09-15 | Ferber Celeste (SVP, GC and Secretary) | Sale | 2,396 | 2.39 | 5,731 |
| 2020-09-15 | Templeman Blaine (Chief Legal Officer) | Sale | 12,369 | 2.39 | 29,586 |
| 2020-09-15 | Isaacs Stephen T (President and CEO) | Sale | 32,481 | 2.39 | 77,694 |
| 2020-08-07 | Nuyten Dimitry Sa (Chief Medical Officer) | Sale | 3,538 | 2.55 | 9,036 |
| 2020-08-07 | Ferber Celeste (SVP, GC and Secretary) | Sale | 7,951 | 2.55 | 20,306 |
| 2020-08-07 | Templeman Blaine (Chief Legal Officer) | Sale | 7,951 | 2.55 | 20,306 |
| 2020-03-18 | Greenman William Mariner | Option Ex | 19,835 | .45 | 8,925 |
| 2020-03-18 | Isaacs Stephen T (President and CEO) | Option Ex | 21,618 | .45 | 9,728 |
| 2020-02-25 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 6,823 | 3.51 | 23,955 |
| 2020-01-03 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 73,311 | 1.19 | 87,093 |
| 2019-12-12 | Ferber Celeste (SVP, GC and Secretary) | Sale | 408 | 1.16 | 474 |
| 2019-12-12 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 2,192 | 1.16 | 2,549 |
| 2019-12-12 | Templeman Blaine (Chief Legal Officer) | Sale | 1,264 | 1.16 | 1,470 |
| 2019-12-12 | Isaacs Stephen T (President and CEO) | Sale | 5,897 | 1.16 | 6,858 |
| 2019-09-16 | Haghighat Ross | Option Ex | 55,539 | .57 | 31,879 |
| 2019-09-13 | Ferber Celeste (SVP, GC and Secretary) | Sale | 2,494 | 1.31 | 3,257 |
| 2019-09-13 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 18,593 | 1.31 | 24,282 |
| 2019-09-13 | Templeman Blaine (Chief Legal Officer) | Sale | 12,878 | 1.31 | 16,818 |
| 2019-09-13 | Isaacs Stephen T (President and CEO) | Sale | 31,098 | 1.31 | 40,613 |
| 2019-05-20 | Ferber Celeste (SVP, GC and Secretary) | Sale | 2,000 | 3.21 | 6,414 |
| 2019-05-01 | Lew Jennifer (Chief Financial Officer) | Sale | 18,602 | 4.20 | 78,128 |
| 2019-05-01 | Lew Jennifer (Chief Financial Officer) | Option Ex | 18,602 | 1.09 | 20,276 |
| 2019-04-08 | Lew Jennifer (Chief Financial Officer) | Sale | 18,601 | 4.07 | 75,761 |
| 2019-04-08 | Lew Jennifer (Chief Financial Officer) | Option Ex | 18,601 | 1.09 | 20,275 |
| 2019-03-19 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 6,081 | 3.96 | 24,105 |
| 2019-02-26 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 6,844 | 4.25 | 29,121 |
| 2018-12-28 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 1,907 | 2.57 | 4,900 |
| 2018-12-12 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 2,171 | 2.93 | 6,365 |
| 2018-12-12 | Templeman Blaine (Chief Legal Officer) | Sale | 1,241 | 2.93 | 3,638 |
| 2018-12-12 | Lew Jennifer (Chief Financial Officer) | Sale | 1,035 | 2.93 | 3,034 |
| 2018-12-12 | Isaacs Stephen T (President and CEO) | Sale | 5,829 | 2.93 | 17,090 |
| 2018-11-20 | Templeman Blaine (Chief Legal Officer) | Sale | 843 | 2.91 | 2,452 |
| 2018-09-24 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 7,726 | 5.83 | 45,019 |
| 2018-09-24 | Templeman Blaine (Chief Legal Officer) | Sale | 10,262 | 5.81 | 59,611 |
| 2018-09-13 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 9,754 | 6.50 | 63,391 |
| 2018-09-13 | Sacks Natalie (Chief Medical Officer) | Sale | 3,028 | 6.50 | 19,678 |
| 2018-09-13 | Templeman Blaine (Executive VP, General Counsel) | Sale | 6,056 | 6.50 | 39,357 |
| 2018-09-13 | Lew Jennifer (Chief Financial Officer) | Sale | 5,623 | 6.50 | 36,543 |
| 2018-09-13 | Isaacs Stephen T (President and CEO) | Sale | 24,143 | 6.50 | 156,905 |
| 2018-09-06 | Isaacs Stephen T (President and CEO) | Sale | 46,987 | 7.92 | 372,043 |
| 2018-09-06 | Isaacs Stephen T (President and CEO) | Option Ex | 46,987 | 1.00 | 46,987 |
| 2018-09-05 | Isaacs Stephen T (President and CEO) | Sale | 15,585 | 7.90 | 123,137 |
| 2018-09-05 | Isaacs Stephen T (President and CEO) | Option Ex | 15,585 | 1.00 | 15,585 |
| 2018-09-04 | Sacks Natalie (Chief Medical Officer) | Sale | 4,504 | 7.13 | 32,100 |
| 2018-07-17 | Van Elsas Andrea (Chief Scientific Officer) | Sale | 10,454 | 6.96 | 72,801 |
| 2018-06-01 | Isaacs Stephen T (President and CEO) | Sale | 40,000 | 8.68 | 347,000 |
| 2018-06-01 | Isaacs Stephen T (President and CEO) | Option Ex | 40,000 | 1.00 | 40,000 |
| 2018-05-17 | Templeman Blaine (Chief Legal Officer) | Sale | 2,000 | 8.15 | 16,300 |
| 2018-05-09 | Isaacs Stephen T (President and CEO) | Sale | 40,000 | 8.01 | 320,360 |
| 2018-05-09 | Isaacs Stephen T (President and CEO) | Option Ex | 40,000 | .91 | 36,400 |
| 2018-04-02 | Isaacs Stephen T (President and CEO) | Sale | 40,000 | 8.91 | 356,400 |
| 2018-04-02 | Isaacs Stephen T (President and CEO) | Option Ex | 40,000 | .82 | 32,800 |
| 2018-03-09 | Isaacs Stephen T (President and CEO) | Sale | 46,417 | 8.80 | 408,376 |
| 2018-03-09 | Isaacs Stephen T (President and CEO) | Option Ex | 46,417 | .54 | 25,204 |
| 2018-03-08 | Isaacs Stephen T (President and CEO) | Sale | 25,634 | 7.95 | 203,790 |
| 2018-03-08 | Isaacs Stephen T (President and CEO) | Option Ex | 25,634 | .45 | 11,535 |
Insider trading activities including stock purchases, stock sales, and option exercises of ADRO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Chinook Therapeutics, Inc. (symbol ADRO, CIK number 1435049) see the Securities and Exchange Commission (SEC) website.